August 18, 2026 – The New Drug Application (NDA) for Progen's independently developed Recombinant Human Serum Albumin Injection (rHSA, indicated for the treatment of cirrhotic ascites) has been formally accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

This acceptance marks the entry of the product's review and approval process into the substantive stage, and represents another key milestone for Progen in its path of independent innovation and industrialization of recombinant protein therapeutics.

Feng Capital participated in Progen's financing round in 2023. Looking ahead, Feng Capital will continue to deepen its presence in the biopharmaceutical sector, driven by in-depth research, and support more innovative drugs in their journey from the laboratory to the global market, ultimately delivering greater clinical benefits to patients.

END

【Disclaimer】

The content herein represents solely the views of the Company based on current publicly available information and materials provided by portfolio companies, and does not constitute any investment advice, medical advice, or guarantee of specific company performance. Investment involves risks; please make independent judgments based on public information. Reproduction or commercial use without authorization is prohibited.